Syros Pharmaceuticals, Inc. SYRS
We take great care to ensure that the data presented and summarized in this overview for Syros Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SYRS
Top Purchases
Top Sells
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SYRS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2024
|
Nancy A Simonian |
SELL
Open market or private sale
|
Direct |
37,070
-90.26%
|
$0
$0.27 P/Share
|
Nov 25
2024
|
Nancy A Simonian |
SELL
Open market or private sale
|
Direct |
134,713
-76.64%
|
$0
$0.27 P/Share
|
Nov 19
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Open market or private sale
|
Direct |
46,657
-100.0%
|
$0
$0.22 P/Share
|
Nov 18
2024
|
Jason Haas Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
137,803
-100.0%
|
$0
$0.21 P/Share
|
Nov 18
2024
|
Conley Chee President & CEO |
SELL
Open market or private sale
|
Direct |
134,797
-100.0%
|
$0
$0.2 P/Share
|
Nov 18
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,099
-100.0%
|
$0
$0.2 P/Share
|
Nov 18
2024
|
Kristin Stephens Chief Development Officer |
SELL
Open market or private sale
|
Direct |
36,133
-100.0%
|
$0
$0.22 P/Share
|
Oct 31
2024
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,104
-14.45%
|
$12,208
$2.09 P/Share
|
Oct 31
2024
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+28.7%
|
-
|
Oct 31
2024
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,707
-6.24%
|
$17,414
$2.09 P/Share
|
Oct 31
2024
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+10.86%
|
-
|
Oct 31
2024
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,624
-3.92%
|
$11,248
$2.09 P/Share
|
Oct 31
2024
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+11.63%
|
-
|
Oct 31
2024
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,776
-35.9%
|
$13,552
$2.09 P/Share
|
Oct 31
2024
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+50.0%
|
-
|
Oct 31
2024
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
40,125
+18.58%
|
-
|
Sep 30
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
3,100
-6.23%
|
$6,200
$2.1 P/Share
|
Sep 30
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.73%
|
-
|
Sep 16
2024
|
Richard A Young |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+20.0%
|
-
|
Sep 16
2024
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+22.23%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 28K shares |
---|---|
Exercise of conversion of derivative security | 261K shares |
Open market or private purchase | 1.1M shares |
Open market or private sale | 597K shares |
---|---|
Payment of exercise price or tax liability | 68.6K shares |